CN101743322A - 含有表达5HTR2C和/或ADAR的细胞的周围组织样品作为5HTR2C mRNA编辑机制改变的标记及其应用 - Google Patents
含有表达5HTR2C和/或ADAR的细胞的周围组织样品作为5HTR2C mRNA编辑机制改变的标记及其应用 Download PDFInfo
- Publication number
- CN101743322A CN101743322A CN200880019753A CN200880019753A CN101743322A CN 101743322 A CN101743322 A CN 101743322A CN 200880019753 A CN200880019753 A CN 200880019753A CN 200880019753 A CN200880019753 A CN 200880019753A CN 101743322 A CN101743322 A CN 101743322A
- Authority
- CN
- China
- Prior art keywords
- mrna
- editor
- 5htr2c
- adar
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (48)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94368507P | 2007-06-13 | 2007-06-13 | |
US60/943,685 | 2007-06-13 | ||
US2323908P | 2008-01-24 | 2008-01-24 | |
US61/023,239 | 2008-01-24 | ||
PCT/EP2008/057519 WO2008152146A1 (en) | 2007-06-13 | 2008-06-13 | Peripherical tissue sample containing cells expressing the 5htr2c and/or adars as markers of the alteration of the mechanism of the 5htr2c mrna editing and its applications |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101743322A true CN101743322A (zh) | 2010-06-16 |
CN101743322B CN101743322B (zh) | 2014-12-24 |
Family
ID=39776384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880019753.XA Active CN101743322B (zh) | 2007-06-13 | 2008-06-13 | 含有表达5HTR2C和/或ADAR的细胞的周围组织样品作为5HTR2CmRNA编辑机制改变的标记及其应用 |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP3272881B9 (zh) |
JP (1) | JP5661458B2 (zh) |
CN (1) | CN101743322B (zh) |
CA (1) | CA2690909C (zh) |
ES (2) | ES2952748T3 (zh) |
WO (1) | WO2008152146A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108779494A (zh) * | 2016-03-11 | 2018-11-09 | 阿利瑟迪亚格公司 | 选择由活性化合物诱导的特定效应的基于rna编辑的算法和体外方法 |
CN110352244A (zh) * | 2016-09-01 | 2019-10-18 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2202321A1 (en) | 2008-12-17 | 2010-06-30 | Biocortech | Evaluation of the potential risk of drug induced mood disturbance and suicide:use of a dedicated platform |
EP2585613B1 (en) | 2010-06-24 | 2021-02-24 | Alcediag | Editing profiling of pde8a pre -mrna : use as specific biomarker of adars activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects |
US11873531B2 (en) * | 2010-06-24 | 2024-01-16 | Alcediag | Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects |
CN102146119A (zh) * | 2011-01-17 | 2011-08-10 | 山东大学齐鲁医院 | 一种小鼠表皮总蛋白的提取方法 |
US20190185937A1 (en) * | 2016-07-28 | 2019-06-20 | Alcediag | Rna editing as biomarkers for mood disorders test |
EP3819386A1 (en) * | 2019-11-08 | 2021-05-12 | Alcediag | Diagnosing of mood disorders using blood rna editing biomarkers |
EP3819387A1 (en) * | 2019-11-08 | 2021-05-12 | Alcediag | Differential diagnosis of bipolar disorder and unipolar depression by blood rna editing biomarkers |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763174A (en) * | 1994-02-17 | 1998-06-09 | The Wistar Institute Of Anatomy & Biology | RNA editing enzyme and methods of use thereof |
FR2842827B1 (fr) * | 2002-07-26 | 2004-10-22 | Biocortech | NOUVELLE METHODE D'ANALYSE D'ACIDE NUCLEIQUE ET SON UTILISATION POUR EVALUER LE DEGRE D'EDITION DE L'ARNm DU RECEPTEUR 5-HT2c |
WO2005087949A1 (en) * | 2004-03-12 | 2005-09-22 | Compugen Ltd. | Systematic mapping of adenosine to inosine editing sites in the human transcriptome |
GB0420873D0 (en) * | 2004-09-20 | 2004-10-20 | Curidium Ltd | Methods of diagnosis |
US20100008921A1 (en) * | 2005-06-16 | 2010-01-14 | Evotec Neurosciences Gmbh | Diagnostic and Therapeutic Target Adarb2 Proteins for Neurodegenerative Diseases |
-
2008
- 2008-06-13 WO PCT/EP2008/057519 patent/WO2008152146A1/en active Application Filing
- 2008-06-13 EP EP17185202.3A patent/EP3272881B9/en active Active
- 2008-06-13 ES ES17185202T patent/ES2952748T3/es active Active
- 2008-06-13 CA CA2690909A patent/CA2690909C/en active Active
- 2008-06-13 EP EP08761038.2A patent/EP2162550B1/en not_active Not-in-force
- 2008-06-13 CN CN200880019753.XA patent/CN101743322B/zh active Active
- 2008-06-13 ES ES08761038.2T patent/ES2646592T3/es active Active
- 2008-06-13 JP JP2010511663A patent/JP5661458B2/ja active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108779494A (zh) * | 2016-03-11 | 2018-11-09 | 阿利瑟迪亚格公司 | 选择由活性化合物诱导的特定效应的基于rna编辑的算法和体外方法 |
CN108779494B (zh) * | 2016-03-11 | 2024-05-14 | 阿利瑟迪亚格公司 | 选择由活性化合物诱导的特定效应的基于rna编辑的算法和体外方法 |
CN110352244A (zh) * | 2016-09-01 | 2019-10-18 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
CN110352244B (zh) * | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
Also Published As
Publication number | Publication date |
---|---|
ES2952748T3 (es) | 2023-11-03 |
ES2646592T3 (es) | 2017-12-14 |
CN101743322B (zh) | 2014-12-24 |
JP5661458B2 (ja) | 2015-01-28 |
CA2690909C (en) | 2022-01-18 |
WO2008152146A1 (en) | 2008-12-18 |
EP2162550B1 (en) | 2017-08-09 |
EP3272881C0 (en) | 2023-06-07 |
JP2010528672A (ja) | 2010-08-26 |
CA2690909A1 (en) | 2008-12-18 |
EP3272881B1 (en) | 2023-06-07 |
EP3272881B9 (en) | 2023-10-04 |
EP3272881A1 (en) | 2018-01-24 |
EP2162550A1 (en) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101743322B (zh) | 含有表达5HTR2C和/或ADAR的细胞的周围组织样品作为5HTR2CmRNA编辑机制改变的标记及其应用 | |
Montecchiani et al. | ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot–Marie–Tooth disease | |
Jiang et al. | Micro-RNA-137 inhibits tau hyperphosphorylation in Alzheimer’s disease and targets the CACNA1C gene in transgenic mice and human neuroblastoma SH-SY5Y cells | |
Kara et al. | Genetic and phenotypic characterization of complex hereditary spastic paraplegia | |
Sakurai et al. | An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia | |
Dwivedi et al. | Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects | |
Lim et al. | Allelic expression of serotonin transporter (SERT) mRNA in human pons: lack of correlation with the polymorphism SERTLPR | |
JP5785697B2 (ja) | Cntf遺伝子多型に基づく、精神病および統合失調症の処置方法 | |
Schiffer et al. | Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder | |
Margoob et al. | Serotonin transporter gene polymorphism and psychiatric disorders: Is there a link? | |
Weissmann et al. | Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression | |
Lombardo et al. | Altered brain sodium channel transcript levels in human epilepsy | |
Owen et al. | Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression | |
Rogelj et al. | Contextual fear conditioning regulates the expression of brain‐specific small nucleolar RNAs in hippocampus | |
Chimienti et al. | Brain region-specific alterations of RNA editing in PDE8A mRNA in suicide decedents | |
Iga et al. | Gene expression and association analysis of LIM (PDLIM5) in major depression | |
Yamada et al. | Antidepressant-elicited changes in gene expression: remodeling of neuronal circuits as a new hypothesis for drug efficacy | |
KR101542907B1 (ko) | Cmt에 대한 원인 유전자로서 plekhg5 및 이를 이용한 상기 질병의 진단 방법 | |
JP2017169571A (ja) | 気分障害および自殺を誘発する、薬剤の潜在的なリスクの評価:専用プラットフォームの使用 | |
Kawarai et al. | Late-onset spastic paraplegia: Aberrant SPG11 transcripts generated by a novel splice site donor mutation | |
Gopinath et al. | A novel locus for distal motor neuron degeneration maps to chromosome 7q34-q36 | |
US20100184058A1 (en) | Peripherical tissue sample containing cells expressing the 5htr2c and/or adars as markers of the alteration of the mechanism of the 5htr2c mrna editing and its applications | |
Lin et al. | A novel deletion mutation in GJB1 causes X‐linked Charcot–Marie–Tooth disease in a Han Chinese family | |
Mitchell et al. | Neonatal lesions of the ventral hippocampal formation alter GABA-A receptor subunit mRNA expression in adult rat frontal pole | |
POLAT et al. | Investigation of neuregulin-1 gen rs6994992 polymorphism in gifted students in Turkish population |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151223 Address after: French Peniye Patentee after: Asif Tiago Co. Address before: French Peniye Patentee before: Mourinho 19 LLC Effective date of registration: 20151223 Address after: French Peniye Patentee after: Mourinho 19 LLC Address before: Paris France Patentee before: Marco Polo pharmaceuticals Effective date of registration: 20151223 Address after: Paris France Patentee after: Marco Polo pharmaceuticals Address before: Paris France Patentee before: Biocortech |